These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 24473399)

  • 1. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
    Kurokawa Y; Sugimoto N; Miwa H; Tsuda M; Nishina S; Okuda H; Imamura H; Gamoh M; Sakai D; Shimokawa T; Komatsu Y; Doki Y; Tsujinaka T; Furukawa H
    Br J Cancer; 2014 Mar; 110(5):1163-8. PubMed ID: 24473399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
    Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I
    Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
    Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
    Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
    Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Endo S; Kurokawa Y; Gamoh M; Kimura Y; Matsuyama J; Taniguchi H; Takeno A; Kawabata R; Kawada J; Masuzawa T; Yamamoto K; Kobayashi K; Sakai D; Shimokawa T; Satoh T
    Anticancer Res; 2019 Feb; 39(2):1059-1065. PubMed ID: 30711995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
    Zhu B; Wu JR; Zhou XP
    Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
    Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
    Honma Y; Shimada Y; Takashima A; Iwasa S; Kato K; Hamaguchi T; Yamada Y; Taniguchi H; Sekine S; Kushima R
    Int J Clin Oncol; 2014 Oct; 19(5):863-70. PubMed ID: 24218279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
    Chua C; Tan IB; Yamada Y; Rha SY; Yong WP; Ong WS; Tham CK; Ng M; Tai DW; Iwasa S; Lim HY; Choo SP
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):397-408. PubMed ID: 26099969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
    Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
    Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
    Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
    Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
    Mori Y; Kataoka H; Ebi M; Adachi K; Yamaguchi Y; Hayashi N; Hirata Y; Sobue S; Ishihara R; Suzuki Y; Mizushima T; Inoue Y; Hasegawa I; Ono S; Hirano A; Kimura Y; Seno K; Ozeki K; Shimura T; Kubota E
    J Gastrointest Cancer; 2022 Dec; 53(4):930-938. PubMed ID: 34550548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
    Kawakami H; Fujitani K; Matsuyama J; Akamaru Y; Tamura S; Endo S; Kimura Y; Makari Y; Tamura T; Sugimoto N; Sakai D; Tsujinaka T; Goto M; Kurokawa Y; Shimokawa T; Satoh T;
    Int J Clin Oncol; 2020 Sep; 25(9):1635-1643. PubMed ID: 32494981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of S-1 plus oxaliplatin 130 mg/m
    Kashiwada T; Shinozaki K; Ueno S; Kawanaka H; Uno F; Okita Y; Fukahori M; Matsushita H; Emi Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Maehara Y; Mori M; Baba E;
    Int J Clin Oncol; 2021 Feb; 26(2):345-354. PubMed ID: 33085058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
    Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
    Okita A; Imai H; Takahashi M; Takahashi H; Umegaki S; Kawamura Y; Hiraide S; Ouchi K; Sato Y; Okada Y; Komine K; Saijo K; Takahashi S; Takahashi M; Shirota H; Ohori H; Gamoh M; Ishioka C
    Tohoku J Exp Med; 2018 Jun; 245(2):123-129. PubMed ID: 29937450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.